Michael Fisher
News
Valo Health and Novo Nordisk to develop novel treatments for cardiometabolic diseases
Novo Nordisk and Valo Health have entered into an agreement to discover and develop novel treatments for cardiometabolic diseases based on Valo’s large human...
Japan approves GSK’s Arexvy, the country’s first RSV vaccine for older adults
Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved GSK's Arexvy (respiratory syncytial virus vaccine, recombinant adjuvanted) for the prevention of RSV (respiratory syncytial...
Researchers awarded over £1m take quantum leap into drug development for muscle wasting disease
A team of researchers have been awarded over £1m to explore the capabilities of quantum computing for developing new drugs for myotonic dystrophy.
The University...
